ALMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the data provided, Alumis Inc (ALMS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong positive catalysts, including bullish analyst ratings, insider buying, and a promising clinical pipeline. Despite some financial challenges, the long-term growth potential outweighs the risks.
The stock exhibits bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating an upward trend. However, the MACD is below 0 and negatively contracting, suggesting some short-term weakness. RSI is at 74.313, in the neutral zone. Key resistance is at 30.006, with support at 27.79. Overall, the technical indicators suggest a moderately bullish trend.
Strong analyst ratings with multiple Buy recommendations and significant price target increases (up to $50).
Positive Phase 3 clinical trial results for envudeucitinib, which positions the company as a leader in TYK2-mediated autoimmune disorders.
Insider buying has surged by 586.17% over the last month, indicating confidence from company insiders.
Bullish moving averages and a 31.51% chance of significant price growth in the next month.
Financial performance shows negative EPS (-1.
and net income (-$110.75M), though there is YoY improvement.
MACD is below 0, indicating potential short-term weakness.
No recent congress trading data or AI trading signals to further validate the buy decision.
In Q3 2025, revenue remained flat YoY at $2.066M. Net income improved by 18.94% YoY but remains negative at -$110.75M. EPS dropped by 38.01% YoY to -1.06. Gross margin is stable at 100%. Despite financial challenges, the company is showing improvement in its net income.
Analysts are overwhelmingly positive on ALMS, with multiple Buy ratings and price targets ranging from $32 to $50. The positive sentiment is driven by strong Phase 3 trial results for envudeucitinib and its potential to dominate the TYK2 inhibitor market.
